ReSynapse Therapeutics

ReSynapse Therapeutics is a biotechnology company developing selective multi-target small molecules for 11 million people with treatment-resistant depression. Our solution involves a validated multi-target approach using single-molecule serotonin modulators targeting four validated receptors. Using systematic computational drug design, we identify compounds that precisely modulate multiple serotonin receptors simultaneously. Our approach combines validated receptor biology with proprietary computational methodologies to create drugs that modulate specific receptor combinations, aiming for faster onset, improved efficacy, and favorable safety profiles.